271 filings
8-K
VNDA
Vanda Pharmaceuticals Inc
7 May 24
Other Events
4:51pm
8-K
VNDA
Vanda Pharmaceuticals Inc
3 May 24
Entry into a Material Definitive Agreement
4:02pm
8-K
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
8-K
VNDA
Vanda Pharmaceuticals Inc
3 Apr 24
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
4:32pm
8-K
VNDA
Vanda Pharmaceuticals Inc
7 Mar 24
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
4:31pm
8-K
0qc48n
21 Feb 24
Departure of Directors or Certain Officers
4:32pm
8-K/A
kxg6zgk0c4o2w4lv5k
16 Feb 24
Special Purpose Abbreviated Financial Statements
4:31pm
8-K
t611 uues
7 Feb 24
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
4:07pm
8-K
a0296b6fk
5 Feb 24
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
4:34pm
8-K
y8iczy1d e97
15 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
olocg gwlk8or0s0
7 Dec 23
Entry into a Material Definitive Agreement
5:19pm
8-K
stf50fr17ge84mj c3mw
8 Nov 23
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:05pm
8-K
uhqkpn6fe9o71wg fbq6
21 Aug 23
Other Events
5:13pm
8-K
m6cfjvowxt0i78
27 Jul 23
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
4:06pm
8-K
m56 8p4m5b2
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:40pm
8-K
q3r9wjv
11 May 23
Other Events
7:01am
8-K
042rqe7s
3 May 23
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
4:05pm
8-K
n48erqi2n zr7
17 Mar 23
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
7:05am
8-K
lf7lyoxrtgdudkd
13 Mar 23
Regulation FD Disclosure
9:25am
8-K
gtuhm
17 Feb 23
Departure of Directors or Certain Officers
4:31pm